Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo

  title={Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo
  author={Tadimeti S Rao and Julie A. Cler and Steven J. Mick and V. M. Dilworth and Patricia C. Contreras and Smriti Iyengar and Paul L. Wood},
  • T. Rao, J. Cler, P. Wood
  • Published 1 December 1990
  • Biology, Chemistry, Medicine
  • Neuropharmacology
Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats.
The aim of the present study was to examine the effect of combined treatment of male Wistar rats with pramipexole and fluoxetine or sertraline in the forced swimming test. The obtained results showed
[Update Opipramol].
In view of the limited availability of (pharmacologic) treatment options for generalized anxiety disorder and particularly somatoform disorders, opipramol should be considered in the treatment of these entities.
Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry.
  • G. Debonnel
  • Psychology, Biology
    Journal of psychiatry & neuroscience : JPN
  • 1993
Evidence suggests that sigma receptors could be involved in the pathophysiology and/or in the treatment of schizophrenia by modulating the glutamatergic inputs, by regulating directly the firing activity of dopaminergic neurons, or by both mechanisms.
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism
BMY-14802 exerts its AIM-suppressing effects via a 5-HT1A agonist mechanism, similar to buspirone, which is a promising candidate for clinical trials due to its extremely low affinity for the D2 receptor and lack of extrapyramidal effects during prior clinical trials for schizophrenia.


Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate.
The data support previous findings that TCAs interact with the NMDA receptor complex and suggest that the compounds trihexyphenidyl and dextromethorphan, which have been shown to block NMDA-mediated neurotoxicity, may produce their effects through an interaction with the PCP receptor, albeit by a different mechanism from that of open-channel blockers.
Blockade of hippocampal dopamine (da) receptors: A tool for antipsychotics with low extrapyramidal side effects
Interaction of L-glutamate and magnesium with phencyclidine recognition sites in rat brain: evidence for multiple affinity states of the phencyclidine/N-methyl-D-aspartate receptor complex.
Analysis of a series of compounds thought to interact with either the NMDA or PCP components of the receptor complex under four binding conditions showed that dissociative anesthetics, such as dexoxadrol and PCP, selectively interact with the high affinity state of the PCP receptor.
Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine.
It is suggested that the high affinity dextromethorphan site ligands can mediate only the nonpsychotomimetic effects of sigma ligands, and further studies are necessary to determine the physiological role and therapeutic potential of the DM high affinity sites.